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Abstract
Understanding and characterizing treatment effect variation in randomized experiments has
become essential for going beyond the “black box” of the average treatment effect. Nonetheless,
traditional statistical approaches often ignore or assume away such variation. In the context of
randomized experiments, this paper proposes a framework for decomposing overall treatment
effect variation into a systematic component explained by observed covariates and a remaining
idiosyncratic component. Our framework is fully randomization-based, with estimates of treat-
ment effect variation that are entirely justified by the randomization itself. Our framework can
also account for noncompliance, which is an important practical complication. We make sev-
eral contributions. First, we show that randomization-based estimates of systematic variation
are very similar in form to estimates from fully-interacted linear regression and two stage least
squares. Second, we use these estimators to develop an omnibus test for systematic treatment
effect variation, both with and without noncompliance. Third, we propose an R2-like measure
of treatment effect variation explained by covariates and, when applicable, noncompliance. Fi-
nally, we assess these methods via simulation studies and apply them to the Head Start Impact
Study, a large-scale randomized experiment.
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1 Introduction
The analysis of randomized experiments has traditionally focused on the average treatment effect,
often ignoring or assuming away treatment effect variation (e.g., Neyman, 1923; Fisher, 1935;
Kempthorne, 1952; Rosenbaum, 2002). Today, understanding and characterizing treatment effect
variation in randomized experiments has become essential for going beyond the “black box” of
the average treatment effect. This is clear from the increasing number of papers on the topic in
statistics and machine learning (Hill, 2011; Athey and Imbens, 2016; Wager and Athey, 2017),
biostatistics (Huang et al., 2012; Matsouaka et al., 2014), education (Raudenbush and Bloom,
2015), economics (Heckman et al., 1997; Crump et al., 2008; Djebbari and Smith, 2008), political
science (Green and Kern, 2012; Imai and Ratkovic, 2013), and other areas.
This paper proposes a framework for decomposing overall treatment effect variation in a ran-
domized experiment into a systematic component that is explained by observed covariates, and an
idiosyncratic component that is not explained (Heckman et al., 1997; Djebbari and Smith, 2008). In
doing so, we make several key contributions. First, we take a fully randomization-based perspective
(see Rosenbaum, 2002; Imbens and Rubin, 2015), and propose estimators that are entirely justified
by the randomization itself. This is in contrast to much of the literature on randomization-based
methods, where treatment effect variation is typically a nuisance (e.g. Rosenbaum, 1999, 2007).
Similar to Lin (2013), we show that the resulting estimator is very similar in form to linear regres-
sion with interactions between the treatment indicator and covariates. Unlike with linear regression,
however, the proposed estimator does not require any modeling assumptions on the marginal out-
comes.
Second, we extend these methods from intention-to-treat (ITT) analysis to allow for noncom-
pliance, proposing a randomized-based estimator for systematic treatment effect variation for the
Local Average Treatment Effect (LATE) in the case of noncompliance (Angrist et al., 1996). We
show that this estimator is nearly identical to the two-stage least squares estimator with interac-
tions between the treatment and covariates. We believe that this is a particularly novel contribution
to the recent literature seeking to reconcile the randomization-based tradition in statistics and the
linear model-based perspective more common in econometrics (Abadie, 2003; Imbens, 2014; Imbens
and Rubin, 2015).
Armed with these estimators, we turn to two practical tools for decomposing treatment effect
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variation. The first is an omnibus test for the presence of systematic treatment effect variation.
While versions of this test have been proposed previously, largely in the context of linear mod-
els (Cox, 1984; Crump et al., 2008), our proposed test is fully randomization-based and can also
account for noncompliance. The second is to develop and bound an R2-like measure of the fraction
of treatment effect variation explained by covariates. This builds on previous versions proposed
in the econometrics literature (Heckman et al., 1997; Djebbari and Smith, 2008), again extending
results to account for noncompliance. This approach is also closely related to the Oaxaca–Blinder
decomposition in economics (Oaxaca, 1973; Blinder, 1973). See Angrist et al. (2013) for a recent
application that also addresses compliance. Finally, we apply these methods to the Head Start
Impact Study, a large-scale randomized trial of Head Start, a federally funded preschool program
(Puma et al., 2010). We relegate the technical details and some further extensions to the online
Supplementary Material.
2 Framework for Treatment Effect Variation
2.1 Setup and notation
Assume that we have n units in an experiment. For unit i, let Xi = (X1i, . . . , XKi)
T ∈ RK denote
the vector of pretreatment covariates, with the constant 1 as its first component. Let Ti denote
the treatment indicator with 1 for treatment and 0 for control. We use the potential outcomes
framework (Neyman, 1923; Rubin, 1974) to define causal effects. Under the Stable Unit Treatment
Value Assumption (Rubin, 1980) that there is only one version of the treatment and no interference
among units, we define Yi(1) and Yi(0) as the potential outcomes of unit i under treatment and
control, respectively. The observed outcome, Y obsi = TiYi(1) + (1 − Ti)Yi(0), is quite general
and includes continuous, binary, and zero-inflated cases. On the difference scale, the individual
treatment effect is τi = Yi(1)− Yi(0).
Importantly, this is finite population inference in that we condition on the n units at hand—the
potential outcomes are fixed and pre-treatment. This differs from super population inference in
which some variables or residuals are assumed to be independent and identically distributed (iid)
draws from some distribution. See, for example, Rosenbaum (2002), Imbens and Rubin (2015)
and Li and Ding (2017). Under the potential outcomes framework, {Yi(1), Yi(0)}ni=1 are all fixed
numbers; the randomness of any estimator comes from the assignment mechanism, which is the
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distribution of possible treatment assignments T = (T1, . . . , Tn)
T. Note that pr{(T1, . . . , Tn) =
(t1, . . . , tn)} =
(
n
n1
)−1
if
∑n
i=1 ti = n1.
2.2 Randomization inference for vector outcomes
To set up our overall framework, we first generalize Neyman (1923)’s classic results to vector
outcomes. We consider a completely randomized experiment, with n1 units assigned to treatment
and n0 units assigned to control; in total we have
(
n
n1
)
possible randomizations. We are interested
in estimating the finite population average treatment effect on a vector outcome V ∈ RK :
τV =
1
n
n∑
i=1
{Vi(1)− Vi(0)} ,
where Vi(1) and Vi(0) are the potential outcomes of V for unit i. The Neyman-type unbiased
estimator for τV is the difference between the sample mean vectors of the observed outcomes under
treatment and control:
τ̂V = V¯
obs
1 − V¯ obs0 =
1
n1
n∑
i=1
TiV
obs
i −
1
n0
n∑
i=1
(1− Ti)V obsi =
1
n1
n∑
i=1
TiVi(1)− 1
n0
n∑
i=1
(1− Ti)Vi(0).
The behavior of our estimator, and of our estimators for heterogeneity discussed later, revolve
around covariances of vector outcomes. For notation, let A = {A1, . . . ,An} be a collection of n
vectors, with A¯ = n−1
∑n
i=1Ai the vector mean, and define the covariance operator on A as
S(A) = 1
n− 1
n∑
i=1
(Ai − A¯)(Ai − A¯)T,
which gives the covariance matrix of the n vectors in A. For example, Ai can be Vi(1),Vi(0) or
Vi(1)− Vi(0).
The following theorem, generalizing the results for scalar outcomes from Neyman (1923), demon-
strates that τ̂V is unbiased and gives its covariance matrix.
Theorem 1. Over all possible randomizations of a completely randomized experiment, τ̂V is
unbiased for τV , with K ×K covariance matrix:
cov(τ̂V ) =
S{V (1)}
n1
+
S{V (0)}
n0
− S{V (1)− V (0)}
n
. (1)
The diagonal elements of this matrix are the variances of the estimators of each component of
τV . The covariance matrix of τ̂V depends on the various covariances of the potential outcomes
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under treatment and control. In particular, the last term depends on the correlation between the
potential outcomes V (1) and V (0), and therefore cannot be identified from the observed data.
When the individual treatment effects are constant for all components of V , the last term in the
above covariance matrix vanishes, because then S{V (1)−V (0)} = 0K×K . Under this assumption,
we can unbiasedly estimate the sampling covariance matrix cov(τ̂V ) by replacing the covariances
of the potential outcomes by the sample analogues:
ĉov(τ̂V ) =
Ŝ1(V obs)
n1
+
Ŝ0(V obs)
n0
,
where
Ŝt(V obs) = 1
nt − 1
n∑
i=1
I(Ti=t)(Vi − V¯ obst )(Vi − V¯ obst )T (t = 0, 1) (2)
are the sample covariance matrices of V obs in the treatment and control groups. Without the
constant treatment effect assumption, the covariance estimator ĉov(τ̂V ) is conservative in the sense
that the difference between the expectation of the variance estimator and the true variance is a
non-negative definite matrix. In particular, the diagonal terms of the expected estimator will all
be larger than the truth. Letting K = 1, the covariance matrices become simple variances, which
recovers Neyman’s original result.
Using the mathematical framework introduced in the Appendix and in Li and Ding (2017), we
can easily generalize Theorem 1 to more complicated experimental designs, e.g., cluster-randomized
trials (Middleton and Aronow, 2015) and unbalanced 22 split-plot designs (Zhao et al., 2017).
2.3 Decomposing Treatment Effect Variation
We now apply this general framework to treatment effect variation. We decompose the individual
treatment effect, τi, via
τi = Yi(1)− Yi(0) = XTiβ + εi, (i = 1, . . . , n) (3)
with β being the finite population linear regression coefficient of τi on Xi, defined by
β = arg min
b∈RK
n∑
i=1
(τi −XTib)2 . (4)
Following Heckman et al. (1997) and Djebbari and Smith (2008), we call δi = X
T
iβ the systematic
treatment effect variation explained by the observed covariates, Xi, and call εi the idiosyncratic
treatment effect variation not explained by Xi.
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More generally, we can view this decomposition in a regression-style framework. Define
Sxx =
1
n
n∑
i=1
XiX
T
i ∈ RK×K , Sxε =
1
n
n∑
i=1
εiXi ∈ RK , Sxτ = 1
n
n∑
i=1
τiXi ∈ RK ,
where Sxx is non-degenerate, analogous to the usual full rank assumption in linear models. Also
define
Sxt =
1
n
n∑
i=1
XiYi(t) ∈ RK , (t = 0, 1).
These are all finite population quantities, as in they are fixed pre-randomization values. The
definition of β gives Sxε = 0, i.e., εi andXi have finite population covariance zero. Therefore, in the
spirit of the agnostic regression framework (e.g., Lin, 2013), the systematic component, δi = X
T
iβ,
is a projection of τi onto the linear space spanned by Xi, and the idiosyncratic treatment effect,
εi, is the corresponding residual. The linear projection applies to general outcomes, including the
binary case.
Because of our finite population focus, if we observed all the potential outcomes we could
immediately calculate all individual treatment effects and apply standard linear regression theory
to (3) and obtain β. In particular, the solution of (4), i.e. the ordinary least squares (OLS) solution
from regressing τ on X, is
β = S−1xx Sxτ = S
−1
xx Sx1 − S−1xx Sx0 ≡ γ1 − γ0, (5)
where γ1 = S
−1
xx Sx1 and γ0 = S
−1
xx Sx0 are the corresponding finite population regression coefficients
of the potential outcomes on the covariates. Let ei(1) = Yi(1)−XTiγ1 and ei(0) = Yi(0)−XTiγ0 be
the residual potential outcomes from the regression of Yi(t) onto X. Our idiosyncratic treatment
variation is then the difference of residuals: εi = ei(1)− ei(0). In practice, we do not fully observe
these components, but we can obtain unbiased or consistent estimates for them as we discuss below.
3 Systematic treatment effect variation for the ITT
3.1 Randomization-based estimator
We now turn to estimating β. As shown in (5), β has three components. The first term, Sxx,
is fully observed as all the covariates are observed. Our estimation then depends on the sample
analogues of Sx1 and Sx0:
Ŝx1 =
1
n1
n∑
i=1
TiY
obs
i Xi ∈ RK , Ŝx0 =
1
n0
n∑
i=1
(1− Ti)Y obsi Xi ∈ RK .
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The Ŝxt’s capture how the observed potential outcomes correlate with the covariates. Plug these
into (5) to obtain an overall estimate of β. The randomization of T then justifies the following
theorem.
Theorem 2. Under decomposition (3), S−1xx Ŝx1 and S−1xx Ŝx0 are unbiased estimates of γ1 and γ0,
respectively. Therefore
β̂RI = S
−1
xx Ŝx1 − S−1xx Ŝx0,
is an unbiased estimator for β with covariance matrix
cov(β̂RI) = S
−1
xx
[S{Y (1)X}
n1
+
S{Y (0)X}
n0
− S(τX)
n
]
S−1xx . (6)
Here, for example, S{Y (0)X} denotes the covariance operator on new unit-level variables
Yi(0)Xi ∈ RK , made by scaling the Xi vector of each unit by Yi(0), similarly for S{Y (1)X}
and S(τX). This slight abuse of notation gives formulae less cluttered by subscripts and excessive
annotation. As with the vector version of Neyman’s formula, the square root of the diagonal of
cov(β̂RI) gives the standard errors of β.
The covariance formula (6) generalizes the result of Neyman (1923) for the average treatment
effect, reducing to Neyman’s formula if Xi = 1 for all units. We can obtain a “conservative”
estimate of cov(β̂RI) by
ĉov(β̂RI) = S
−1
xx
[
Ŝ1(Y obsX)
n1
+
Ŝ0(Y obsX)
n0
]
S−1xx ,
recalling the definitions of the sample covariance operators Ŝ1 and Ŝ0 introduced in (2). Similar
to Neyman (1923), this implicitly assumes S(τX) = 0. Under the assumption that εi = 0 for all
units (i.e., no idiosyncratic variation whatsoever), we can instead use S(τ̂X) with τ̂ = XTi β̂RI as a
plug-in estimate for S(τX). This yields tighter standard errors based on the diagonal elements of
the covariance matrix.
Finite population asymptotic analysis Theorem 2 holds for any finite sample. To obtain
confidence intervals and to conduct hypothesis testing as we describe below, we need to prove fur-
ther that β̂RI is asymptotically normal with mean β and covariance cov(β̂RI). Finite population
asymptotic analysis, however, has a slightly different flavor from the usual super population ap-
proach. Formally, the finite asymptotic scheme embeds the finite population {(Xi, Yi(1), Yi(0))}ni=1
7
with size n into a hypothetical sequence of finite populations with sizes approaching infinity. This
effectively assumes that all the finite population quantities, for example, Sxx and β, depend on
n, although they are fixed numbers for a given finite population. Moreover, the sample quantities
such as Ŝx1 and β̂RI depend on n as well, and are random quantities due to the randomization of
T . For notational simplicity, we drop the index n for all these quantities. Importantly, we must
impose some regularity conditions on the hypothetical sequence of finite populations. Throughout
the paper, we invoke the following conditions for asymptotic analysis, which are required for a form
of the finite population central limit theorem discussed in Li and Ding (2017, Theorem 5).
Condition 1. (i) Stable treatment proportions: p1 = n1/n and p0 = n0/n have positive limiting
values; (ii) Stable means, variances and covariances: the finite population means, variances and
covariances of the covariates and potential outcomes have finite limiting values; (iii) max1≤i≤n ||Vi−
V¯ ||22/n→ 0, where Vi can be the covariate vector, the outcome, and the products of them.
Under these conditions, we can extend Theorem 2 to a sequence of finite populations:
√
n
(
β̂RI − β
)
d→ N
(
0, lim
n→∞ [p1S{Y (1)X}+ p0S{Y (0)X} − S(τX)]
)
. (7)
As a result, we can state that β̂RI is approximately normal with mean β and covariance matrix
(6), which allows us to construct confidence intervals and hypothesis tests. In our theory below,
we use this informal statement instead of (7) to avoid notational complexity.
Conditions (i) and (ii) are natural. Condition (iii) holds if V has more than two moments (Li
and Ding, 2017). For bounded covariates and outcomes, (iii) is satisfied automatically. For more
technical discussion of finite population causal inference, see Ding (2014), Aronow et al. (2014),
and Middleton and Aronow (2015); for regularity conditions of the finite population central limit
theorems, see Ha´jek (1960) and Lehmann (1998). A recent review is Li and Ding (2017).
3.2 Regression with treatment-covariate interactions
The results from randomization inference can shed light on the familiar case of linear regression
with treatment-covariate interactions. This classical approach assumes the model
Y obsi = X
T
iγ + TiX
T
iβ + ui, (i = 1, . . . , n) (8)
where {ui}ni=1 are errors implicitly assumed to induce the randomness, and where β models sys-
tematic treatment effect variation, as in (3). Departing from much of the previous literature (e.g.,
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Cox, 1984; Berrington de Gonza´lez and Cox, 2007; Crump et al., 2008), we study the properties
of the least squares estimator under complete randomization, without assuming that model (8) is
correctly specified. In particular, we do not assume any i.i.d. sampling; the assignment mechanism
drives the distribution of the OLS estimator.
Theorem 3. The OLS estimator for β from fitting model (8) can be rewritten as
β̂OLS = Ŝ
−1
xx,1Ŝx1 − Ŝ−1xx,0Ŝx0,
where
Ŝxx,t =
1
nt
n∑
i=1
I(Ti=t)XiX
T
i , (t = 0, 1).
Over all possible randomizations of T , Ŝ−1xx,1Ŝx1 and Ŝ
−1
xx,0Ŝx0 are consistent estimates of γ1 and γ0
respectively; β̂OLS therefore follows an asymptotic normal distribution with mean β and covariance
matrix
cov(β̂OLS) = S
−1
xx
[S{e(1)X}
n1
+
S{e(0)X}
n0
− S(εX)
n
]
S−1xx . (9)
with ei(1), ei(0), and εi as defined after (5).
This estimate is simply the difference between γ̂1,OLS = Ŝ
−1
xx,1Ŝx1 and γ̂0,OLS = Ŝ
−1
xx,0Ŝx0,
two OLS regressions run separately on each treatment arm. For treated units, define residual
êi = Y
obs
i −XTi γ̂1,OLS, and for control units, define residual êi = Y obsi −XTi γ̂0,OLS. We can drop
the unidentifiable term S(εX), estimate S{e(1)X} and S{e(0)X} by their sample analogues, and
conservatively estimate the asymptotic covariance matrix (9) by
ĉov(β̂OLS) = Ŝ
−1
xx,1
[
Ŝ1(êX)
n1
]
Ŝ−1xx,1 + Ŝ
−1
xx,0
[
Ŝ0(êX)
n0
]
Ŝ−1xx,0.
This form of the sandwich variance estimator has the same probability limit as the HuberWhite
covariance estimator for linear model (8) (Huber, 1967; White, 1980; Lin, 2013; Angrist and Pischke,
2008).
Importantly, β̂RI and β̂OLS are quite similar in form. In particular, β̂RI uses the true Sxx while
β̂OLS separately estimates the covariance matrix for each treatment arm, Ŝxx,0 and Ŝxx,1. The latter
is effectively a ratio estimator. Although this introduces some small bias (on the order of 1/n),
using the estimated Ŝxx,t rather than true Sxx can often lead to gains in precision, especially when
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covariates are strongly correlated with the potential outcomes. In particular, the OLS estimator,
by separately estimating the (known) Sxx matrix for each treatment arm, can account for random
imbalances in the covariates in both arms.
The RI estimator, by comparison, has no adjustment whatsoever, and so cannot account for such
random covariate imbalances. However, in Section 3.4 below, and in the supplementary materials
we introduce a different form of adjustment that uses covariates to make the estimates of the Sxt
more precise. Depending on the structure of covariates, this estimator could be better or worse
than OLS adjustment; we leave a thorough investigation of these trade-offs for future work.
Regardless, we again emphasize that we do not rely on classical OLS assumptions to justify
the OLS estimator here. Rather, randomization (plus some mild regularity conditions for the
finite sample asymptotics) justify our results. For related discussion, see Cochran (1977) on ratio
estimators in surveys.
3.3 Omnibus test for systematic variation
Finally, we can use these results to develop an omnibus test for the presence of any systematic
treatment effect variation. The null hypothesis of no treatment effect variation explained by the
observed covariates can be characterized by
H0(X) : β1 = 0,
where β1 contains all the components of β except the first component corresponding to the inter-
cept. Under H0(X), the individual treatment effects have no linear dependance on X.
We then construct a Wald-type test for H0(X) using an estimator β̂ and its covariance estimator
ĉov(β̂); it could be β̂RI or β̂OLS. Let β̂1 and ĉov(β̂1) denote the sub-vector of β̂ and sub-matrix of
ĉov(β̂), corresponding to the non-intercept coordinates of X. We reject when
β̂T1ĉov
−1(β̂1)β̂1 > qK−1(1− α), (10)
where qK−1(1− α) is the 1− α quantile of the χ2 random variable with degrees of freedom K − 1.
The test in (10) is nearly identical to the test proposed by Crump et al. (2008). They relax the
parametric assumption by taking a “sieve estimator” approach, namely by using a quadratic form of
the regression function, which allows for more flexible marginal distributions. Our approach differs
in that we avoid modeling the marginal distributions entirely. If desired, we can add polynomials
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of X (or other basis functions) into the model for δ to allow for more flexible systematic treatment
effect variation, which could enhance power or model more complex relationships between the bX
and treatment impact.
3.4 Additional considerations
In the Supplementary Material, we describe two additional points about systematic treatment
effect variation that we briefly address here. First, as mentioned above, we can use model-assisted
estimation to improve the randomization-based estimator. In particular, improving estimation
of Ŝxt directly improves β̂RI, as the Ŝxt are the only random components. In particular, if we
replace the standard sample estimator, Ŝxt, by a more efficient, model-assisted estimator, as in
survey sampling (Cochran, 1977; Sa¨rndal et al., 2003), we can achieve meaningful precision gains
in practice. More importantly, this setup allows researchers to assess systematic variation across
one set of covariates while adjusting for another set.
Second, under the assumption of no idiosyncratic variation (i.e., εi = 0 for all i), we can ob-
tain exact inference for β by inverting a sequence of randomization-based tests. This complements
previous work on randomization-based tests for the presence of idiosyncratic treatment effect vari-
ation (Ding et al., 2016).
4 Idiosyncratic treatment effect variation for ITT
After characterizing the systematic component of treatment effect variation, we now turn to char-
acterizing the idiosyncratic component. Since this quantity is inherently unidentifiable, we propose
sharp bounds on this component and a framework for sensitivity analysis. We then leverage these
results to bound an R2-like measure of the treatment effect variation explained by covariates.
4.1 Bounds
We first define the main quantities of interest:
Sττ =
1
n
n∑
i=1
(τi − τ)2, Sδδ = 1
n
n∑
i=1
(δi − τ)2, Sεε = 1
n
n∑
i=1
ε2i ,
with δi and εi defined as in (3). Then Sττ = Sδδ + Sεε. We can immediately estimate Sδδ via
the sample variance of {δ̂i = XTi β̂}ni=1, where β̂ is a consistent estimator, e.g., β̂RI or β̂OLS.
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However, the idiosyncratic variance, Sεε, is inherently unidentifiable because it depends on the
joint distribution of potential outcomes.
We can, however, derive sharp bounds for Sεε. Let F1(y) and F0(y) be the empirical cumulative
distribution functions of {ei(1)}ni=1 and {ei(0)}ni=1. Below we denote e(t) as a random variable tak-
ing equal probabilities on n values of {ei(t)}ni=1. Based on the Fre´chet–Hoeffding bounds (Hoeffding,
1941; Fre´chet, 1951; Nelsen, 2007), we can bound Sεε as follows.
Theorem 4. Sεε has sharp bounds Sεε ≤ Sεε ≤ Sεε, where
Sεε =
∫ 1
0
{F−11 (u)− F−10 (u)}2du, Sεε =
∫ 1
0
{F−11 (u)− F−10 (1− u)}2du
with F−1(u) = inf{x : F (x) ≥ u} as the quantile function. The lower and upper bounds are
attainable when e(1) and e(0) have the same ranks and opposite ranks, respectively.
The lower bound of Sεε corresponds to a rank-preserving relationship between e(1) and e(0),
and the upper bound of Sεε corresponds to an anti-rank-preserving relationship between e(1) and
e(0). Equivalently, they correspond to the cases where the Spearman rank correlation coefficients
between e(1) and e(0) are +1 and −1.
In practice, we can often sharpen these bounds because we are unlikely to have negatively
associated potential outcomes after adjusting for covariates. If we assume a nonnegative correlation
between e(1) and e(0), we have the following corollary:
Corollary 1. If the correlation between e(1) and e(0) is nonnegative, then the bounds for Sεε
become Sεε ≤ Sεε ≤ V1 + V0, where Vt is the variance of e(t) for t = 0, 1.
We can consistently estimate each quantity: Sδδ by the sample variance of X
T
i β̂, Fe1(y) and
Fe0(y) by F̂1(y) and F̂0(y), the empirical cumulative distribution functions of the residuals êi under
treatment and control, and V1 and V0 by the variances of ê(1) and ê(0).
Variance of the overall ITT estimator. We can use these results to obtain sharper bounds
on the variance of Neyman (1923)’s estimate of overall ITT, τ̂ = n−11
∑n
i=1 TiY
obs
i − n−10
∑n
i=1(1−
Ti)Y
obs
i , extending previous work by Heckman et al. (1997) and Aronow et al. (2014). See also Fog-
arty (2016). Applying the results in Section 2 for scalar outcomes, we have the following variance
for the difference-in-means estimator,
var(τ̂) =
S11
n1
+
S00
n0
−
(
Sδδ
n
+
Sεε
n
)
,
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where Sττ = Sδδ+Sεε. As we discuss above, Neyman (1923) proposed a lower bound for the overall
var(τ̂) under the assumption of a constant treatment effect, Sττ = 0. More recently, Aronow et al.
(2014) instead proposed to bound Sττ via Fre´chet–Hoeffding bounds. We can modestly improve
these results by applying Fre´chet–Hoeffding bounds for Sεε alone rather than for Sττ = Sδδ + Sεε.
So long as Sδδ > 0, this yields strictly tighter bounds on var(τ̂) than the corresponding bounds
that do not incorporate covariate information. In turn, this gives a tighter estimate of the standard
error for the same difference-in-means estimator, τ̂ .
A variance ratio test. Finally, while the relationship between e(0) and e(1) is inherently uniden-
tifiable, there is some information in the data about the relationship between εi, the individual-level
idiosyncratic treatment effect, and Yi(0), the control potential outcome. In particular, Raudenbush
and Bloom (2015) noted that if the variance of the treatment potential outcomes is smaller than
the variance of the control potential outcomes, then the treatment effect must be negatively asso-
ciated with the control potential outcomes. In the Supplementary Material, we extend this result
to incorporate covariates and propose a formal test.
4.2 Sensitivity analysis
Going beyond worst-case bounds, we can assess the sensitivity of our estimate of Sεε to differ-
ent assumptions of the dependence between potential outcomes. Using the probability integral
transformation, we represent the residual potential outcomes as
e(1) = F−11 (U1), e(0) = F
−1
0 (U0), U1, U0 ∼ Uniform(0, 1),
Therefore, the dependence of the potential outcomes is determined by the dependence of the uniform
random variables U1 and U0, which are the standardized ranks of the potential outcomes. When
U1 = U0, Sεε attains the lower bound Sεε; when U1 = 1 − U0, Sεε attains the upper bound Sεε;
when U1 U0, Sεε attains the improved upper bound V1 + V0.
Rather than simply examine extreme scenarios of Sεε, we can instead represent U1 as a mixture
of U0 and another independent uniform random variable V0 :
U1 ∼ ρU0 + (1− ρ)V0, U0, V0 i.i.d.∼ Uniform(0, 1), (11)
which the sensitivity parameter ρ captures the association between U1 and U0. An immediate
interpretation of ρ is the proportion of rank preserved units, with the other 1− ρ as the proportion
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of units with independent treatment and control residual outcomes. When ρ = 0, U1 U0, and
the residual potential outcomes are independent; when ρ = 1, U1 = U0, and the residual potential
outcomes have the same ranks. The values between (0, 1) corresponds to positive rank correlation
but not full rank preservation. Note that the representation of the joint distribution is not unique,
because we can choose any copula as a joint distribution of (U1, U0) (Nelsen, 2007). We choose the
above representation and notation ρ for the following theorem.
Theorem 5. If Equation 11 holds, then ρ is Spearman’s rank correlation coefficient between e(1)
and e(0). Furthermore, Sεε is a linear function of ρ:
Sεε(ρ) = ρSεε + (1− ρ)(V1 + V0).
We cannot extract any information about ρ from the data. We therefore treat ρ as a sensitivity
parameter, choose a plausible range of ρ, and obtain corresponding values for Sεε.
4.3 Fraction of treatment effect variation explained
A natural question is the relative magnitudes of Sδδ and Sεε (Djebbari and Smith, 2008). Continuing
the regression analogy, this is an R2-like measure for the proportion of total treatment effect
variation explained by the systematic component:
R2τ =
Sδδ
Sττ
=
Sδδ
Sδδ + Sεε
,
which is the ratio between the finite population variances of δ and τ. As above, we can directly
estimate Sδδ but must bound Sεε. Applying Theorem 4, we obtain the following bounds on R
2
τ .
Corollary 2. The sharp bounds on R2τ are
Sδδ
Sδδ + Sεε
≤ R2τ ≤
Sδδ
Sδδ + Sεε
.
If we further assume that the correlation between e(1) and e(0) is nonnegative, the sharp bounds
on R2τ are
Sδδ
Sδδ + V1 + V0
≤ R2τ ≤
Sδδ
Sδδ + Sεε
.
We estimate these bounds via plug-in estimates. Note that Djebbari and Smith (2008) explore
a similar quantity by using a permutation approach to approximate the Fre´chet–Hoeffding upper
and lower bounds. Finally, we can use the sensitivity results for Sεε, with values of ρ ∈ [0, 1]:
R2τ (ρ) =
Sδδ
Sδδ + Sεε(ρ)
.
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5 Noncompliance
5.1 Setup
We now extend our results to allow for noncompliance. Let T be the indicator of treatment
assigned, D be the indicator of treatment received, Y be outcome of interest, andX be pretreatment
covariates. Under the Stable Unit Treatment Value Assumption, we define Di(t) and Yi(t) as
the potential outcomes for unit i under treatment assignment t. Following Angrist et al. (1996)
and Frangakis and Rubin (2002), we can classify units into four compliance types based on the
joint values of Di(1) and Di(0):
Ui =

Always Taker (a) if Di(1) = 1, Di(0) = 1,
Never Taker (n) if Di(1) = 0, Di(0) = 0,
Complier (c) if Di(1) = 1, Di(0) = 0,
Defier (d) if Di(1) = 0, Di(0) = 1.
Denote ni and piu by the number and proportion of compliance types piu of stratum U = u for
u = a, n, c, d.
Throughout our discussion, we invoke the following assumptions which are commonly used for
analyzing randomized experiments with noncompliance.
Assumption 1. (i) Monotonicity: Di(1) ≥ Di(0); (ii) Exclusion restrictions for Always Takers and
Never Takers: Yi(1) = Yi(0) for all units with Di(1) = Di(0); (iii) Strong instrument: pic > C0 > 0,
where C0 is a positive constant independent of the sample size.
Monotonicity rules out the existence of Defiers, i.e., pid = 0. Under monotonicity, we can
estimate the proportion piu using the observed counts of units classified by T and D: let ntd = #{i :
Ti = t,Di = d}, and then pin = n10/n1, pia = n01/n0, and pic = n11/n1 − n01/n0. The exclusion
restrictions assume that treatment assignment has no effect on the outcome for Always Takers and
Never Takers. As a result, treatment effect variation is trivially zero for Always Takers and Never
Takers. Note that this is the unit-level exclusion restriction imposed in Angrist et al. (1996). This
can be relaxed in other settings; for example, we could assume the impact of randomization for these
groups is zero on average (see Imbens and Rubin, 2015). Finally, to avoid technical complexity, we
rule out the weak instrument case (Bound et al., 1995; Staiger and Stock, 1997), i.e., pic is within
a small neighborhood of 0 with radius shrinking to 0.
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We are interested in treatment effect variation among Compliers, which motivates the following
decomposition:
τi = Yi(1)− Yi(0) =
{
0, if Ui = a or n,
XTiβc + εi, if Ui = c,
(12)
where βc is the regression coefficient of τi on Xi among Compliers, analogous to (3).
5.2 Systematic treatment effect variation among Compliers
5.2.1 Randomization inference
We now extend the results of Section 3 to estimate systematic treatment effect variation among
Compliers. Define
Sxx,u =
1
nu
n∑
i=1
I(Ui=u)XiX
T
i , Sxt,u =
1
nu
n∑
i=1
I(Ui=u)Yi(t)Xi, (t = 0, 1;u = a, c, n).
Then, analogous to (5),
βc = S
−1
xx,c(Sx1,c − Sx0,c) = S−1xx,cSx1,c − S−1xx,cSx0,c ≡ γ1c − γ0c, (13)
where
γ1c = S
−1
xx,cSx1,c, γ0c = S
−1
xx,cSx0,c
are the linear regression coefficients of Y (1) and Y (0) on covariates among Compliers.
Unlike in the ITT case, we cannot estimate these quantities directly. Instead, following standard
results from noncompliance (e.g., Angrist et al., 1996; Abadie, 2003; Angrist and Pischke, 2008),
we use estimates from observed subgroups to estimate the desired quantities of interest. Define
sample moments:
Ŝxx,td =
1
nt
n∑
i=1
I(Ti=t)I(Di=d)XiX
T
i , Ŝxt,td =
1
nt
n∑
i=1
I(Ti=t)I(Di=d)Y
obs
i Xi (t, d = 0, 1). (14)
The following theorem connects these quantities with the finite population quantities in (13).
Theorem 6. Over all possible randomizations of a completely randomized experiment, both
Ŝxx(1) = Ŝxx,11 − Ŝxx,01 and Ŝxx(0) = Ŝxx,00 − Ŝxx,10 are unbiased for picSxx,c, and
E(Ŝx1,11 − Ŝx0,01) = picSx1,c, E(Ŝx0,00 − Ŝx1,10) = picSx0,c. (15)
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This theorem shows that we can obtain unbiased estimates for all terms in (13). The following
corollary shows that we can then obtain consistent estimates for γ1c, γ0c, and βc, recalling that in
the asymptotic analysis, we need to embed {Xi, Yi(1), Yi(0), Di(1), Di(0)}ni=1 into a hypothetical
sequence of finite populations under Condition 1.
Corollary 3. γ̂1c,RI = Ŝ
−1
xx (1)(Ŝx1,11 − Ŝx0,01) and γ̂0c,RI = Ŝ−1xx (0)(Ŝx0,00 − Ŝx1,10) are consistent
for γ1c and γ0c. Furthermore, β̂c,RI = γ̂1c,RI− γ̂0c,RI is consistent for βc and follows an asymptotic
normal distribution with covariance matrix
cov(β̂c,RI) = (picSxx,c)
−1
[S{e′(1)X}
n1
+
S{e′(0)X}
n0
− S(εX)
n
]
(picSxx,c)
−1, (16)
where we define the residual potential outcomes to be:
e′i(1) =

Yi(1)−XTiγ1c,
Yi(1)−XTiγ0c,
Yi(1)−XTiγ1c,
e′i(0) =

Yi(0)−XTiγ1c, Ui = a,
Yi(0)−XTiγ0c, Ui = n,
Yi(0)−XTiγ0c, Ui = c.
(17)
The idiosyncratic variation is εi = e
′
i(1) − e′i(0) for unit i, with εi = 0 for Never Takers and
Always Takers, and with εi for Compliers as in (12). The two sets of residuals are not formed from
a regression on all units, but instead the population regression on Compliers alone. As in the ITT
case, we can estimate S{e′(1)X} and S{e′(0)X} using their sample analogues; S(εX), however, is
unidentifiable. For units with Di = 1, we define the residual ê
′
i = Y
obs
i −XTi γ̂c1,RI, and for units
with Di = 0, we define the residual ê
′
i = Y
obs
i −XTi γ̂c0,RI. Therefore, we can obtain a conservative
estimate for the asymptotic covariance (16) by the following sandwich form:
ĉov(β̂c,RI) = Ŝ
−1
xx (1)
[
Ŝ1(ê′X)
n1
]
Ŝ−1xx (1) + Ŝ
−1
xx (0)
[
Ŝ0(ê′X)
n0
]
Ŝ−1xx (0).
As with the ITT analog, so long as we have Assumption 1, randomization itself fully justifies the
theorem and estimators without relying on a model of the observed outcomes.
5.2.2 Two-Stage Least Squares
We now turn to the standard two-stage least squares (TSLS) setting in econometrics (e.g., Angrist
and Pischke, 2008). First, we impose a linear regression model with treatment-covariate interac-
tions:
Y obsi = X
T
iγ +DiX
T
iβ + ui (i = 1, . . . , n).
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Here, the randomness of the observed outcome comes from the randomness of Di and ui. In the
language of econometrics, the treatment received is “endogenous,” i.e., Di and the error term ui
are assumed to be correlated; we therefore use Ti as an instrument for Di. The TSLS estimates
(γ̂TSLS, β̂TSLS) are the solutions to the following estimating equations:
n−1
n∑
i=1
(
Xi
TiXi
)
(Y obsi −XTi γ̂TSLS −DiXTi β̂TSLS) = 0. (18)
This approach is based on M -estimation, though there are many other ways to formalize the
TSLS estimator (e.g., Imbens, 2014). The following theorem shows that the fully-interacted TSLS
estimator β̂TSLS is consistent for βc across randomizations.
Theorem 7. Over all randomizations, the TSLS estimator β̂TSLS follows an asymptotic normal
distribution with mean βc and covariance matrix
(picSxx,c)
−1
[S{e′′(1)X}
n1
+
S{e′′(0)X}
n0
− S(εX)
n
]
(picSxx,c)
−1,
where the residual potential outcomes are defined as
e′′i (1) =

Yi(1)−XTi (γ∞ + βc),
Yi(1)−XTiγ∞,
Yi(1)−XTi (γ∞ + βc),
e′′i (0) =

Yi(0)−XTi (γ∞ + βc), Ui = a,
Yi(0)−XTiγ∞, Ui = n
Yi(0)−XTiγ∞, Ui = c,
where γ∞ is the probability limit of the TSLS regression coefficient, γ̂TSLS, and the idiosyncratic
treatment effect is εi ≡ e′′i (1)− e′′i (0).
For variance estimation, define the residual as ê′′i = Y
obs
i −XTi (γ̂TSLS + β̂TSLS) for units with
Di = 1 and ê
′′
i = Y
obs
i −XTi γ̂TSLS for units with Di = 0. We can then use the following sandwich
variance estimator
ĉov(β̂TSLS) = Ŝ
−1
xx (1)
[
Ŝ1(ê′′X)
n1
]
Ŝ−1xx (1) + Ŝ
−1
xx (0)
[
Ŝ0(ê′′X)
n0
]
Ŝ−1xx (0),
which has the same probability limit as the Huber–White covariance estimator for β̂TSLS. Therefore,
the randomization itself effectively justifies the use of TSLS for estimating systematic treatment
effect variation among Compliers, extending our ITT results.
Finally, while β̂TSLS is a consistent estimator for βc, γ̂TSLS is not, in general, a consistent
estimator for γc0; that is, γ∞ 6= γc0. Instead, γ̂TSLS converges to γ∞ = S−1xx Sx0 − piaS−1xx Sxx,aβc.
In the special case of one-sided noncompliance (i.e., pia = 0), γ∞ = γ0 = S−1xx Sx0, the population
OLS regression coefficient, among all Compliers and Never Takers, of Y (0) on covariates.
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5.2.3 Omnibus test for systematic treatment effect variation among Compliers
With point estimate β̂ and covariance estimate ĉov(β̂) for βc, we can use the same Wald-type χ
2
test as in (10) for the presence of systematic treatment effect variation among Compliers. Here, the
estimator can be either randomization-based β̂c,RI or TSLS estimator β̂TSLS; the degrees of freedom
are the same, K − 1. Unlike in the ITT case, we are not aware of existing tests for systematic
treatment effect variation among Compliers.
5.3 Idiosyncratic treatment effect variation with noncompliance
5.3.1 Bounding idiosyncratic variation
We now turn to decomposing the overall treatment effect in the presence of noncompliance. In
this setting, we have three sources of treatment effect variation: (i) systematic treatment effect
variation among Compliers, (ii) idiosyncratic treatment effect variation among Compliers, and (iii)
treatment effect variation due to noncompliance.
First, recall that total treatment effect variation is Sττ =
∑n
i=1(τi − τ)2/n. We can define a
similar quantity among Compliers:
Sττ,c =
1
nc
n∑
i=1
I(Ui=c)(τi − τc)2.
As in Section 4, we can decompose this variation into systematic and idiosyncratic treatment effect
variation for Compliers, respectively:
Sδδ,c =
1
nc
n∑
i=1
I(Ui=c)(δi − τc)2, Sεε,c =
1
nc
n∑
i=1
I(Ui=c)ε
2
i .
Because treatment effects for Never Takers and Always Takers are zero, there is no treatment effect
variation for these units. The component of treatment effect variation due to compliance status is
Sττ,U =
∑
u=c,a,n
piu(τu − τ)2.
Using τa = τn = 0 and τ = picτc due to the exclusion restrictions, we have the following theorem
summarizing the relationships among the above components.
Theorem 8. Sττ = picSττ,c + Sττ,U , Sττ,c = Sδδ,c + Sεε,c, and Sττ,U = pic(1− pic)τ2c .
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In words, total treatment effect variation has three parts: (i) systematic treatment effect vari-
ation among Compliers, picSδδ,c; (ii) idiosyncratic treatment effect variation among Compliers,
picSεε,c; (iii) treatment effect variation due to noncompliance, Sττ,U .
As in the ITT case, even though Sεε,c is not identifiable, we can derive bounds in terms of
the marginal distributions of the residuals, {e′i(1) = Yi(1) − XTiγ1c : Ui = c, i = 1, . . . , n} and
{e′i(0) = Yi(0) −XTiγ0c : Ui = c, i = 1, . . . , n}, denoted by F1c(y) and F0c(y), and with marginal
variances, V1c and V0c. Once we estimate these quantities, we can plug them in to Theorem 4
and Corrolary 1 to get our bounds. As compliance status is only partially observed, we have
to estimate these quantities by differencing observed distributions; we defer this and some other
technical details to the Supplementary Material.
5.3.2 Treatment effect decomposition
Since there are two sources of variation—covariates and noncompliance—there are three possible
R2-type measures. First, we can measure the treatment effect variation explained by noncompliance
alone (i.e., only U):
R2τ,U =
Sττ,U
Sττ
=
Sττ,U
Sττ,U + picSττ,c
=
Sττ,U
Sττ,U + picSδδ,c + picSεε,c
.
Second, we can measure the proportion of treatment effect variation among Compliers explained
by covariates (i.e., only X):
R2τ,c =
Sδδ,c
Sττ,c
=
Sδδ,c
Sδδ,c + Sεε,c
.
Third, we can measure the treatment effect variation explained by covariates and noncompliance
(i.e., both X and U):
R2τ,UX =
Sττ,U + picSδδ,c
Sττ
=
Sττ,U + picSδδ,c
Sττ,U + picSδδ,c + picSεε,c
.
For each measure, we can use tailored versions of Corollary 1 to construct bounds, or conduct
sensitivity analysis as in Section 4.2, with the sensitivity parameter expressed as the Spearman
correlation between the treatment and control potential outcomes among Compliers.
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6 Simulation study
6.1 ITT estimators
We simulate completely randomized experiments to evaluate the finite sample performance of the
tests for systematic treatment effect variation based on β̂OLS, β̂RI, and β̂
w
RI, the model-assisted
version discussed in the Supplementary Material. Our data generation process is inspired by the
Head Start Impact Study (HSIS) study analyzed in the next section. For a given sample size, we
first generate four independent covariates (X1, a standard normal, X2, a binary covariate with
probability 0.5 being 1, X3, a binary covariate with probability 0.25 being 1, and X4, a standard
normal). The control potential outcomes are then generated from
Yi(0) = 0.3 + 0.2X1i + 0.3X2i − 0.4X3i + 0.8X4i + ui, ui ∼ N (0, σ2).
We select σ2 = 0.26 to make the marginal variance for the control potential outcomes 1; thus
we can interpret impacts in “effect size” units. The R2 of regressing Y (0) onto the covariates is
approximately 0.74, due to the “pre-test”-like variable X4i. Without X4i, the R
2 is about 0.09.
The treatment effects are τi = δi+εi, with (i) either δi = 0.3 for all i, or δi = 0.2+0.1X1i+0.4X3i;
and (ii) either εi = 0 for all i, or εi ∼ N (0, 0.22). All combinations of these two options give the four
cases of (a) no treatment effect variation, (b) only systematic variation, (c) idiosyncratic variation
with no systematic variation, and (d) both systematic and idiosyncratic variation. For an α-level
test of systematic variation, scenarios (a) and (c) should only reject at rate α, while we would like to
see high rejection rates for scenarios (b) and (d). For scenario (d), the R2τ is about 0.5; systematic
variation explains a good share of the overall variation.
To generate a synthetic dataset we generated all potential outcomes, randomized units into
treatment with probability 0.6, and then calculated the corresponding observed outcomes. We then
conducted a test for systematic variation using each of our three estimators. For β̂RI and β̂OLS we
use X1, X2, X3. For our covariate-adjusted estimator β̂
w
RI we also include the fairly predictive X4
for adjustment.
Figure 1 shows the power of these tests, with α = 0.05, for different sample sizes. First,
all estimators appear asymptotically valid, consistent with the theoretical results. The OLS and
adjusted estimators are slightly anti-conservative for small n, however, with rejection rates of
around 9%. Second, the OLS estimator appears to have the greatest power in this setting, which is
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Figure 1: Power of the tests based on β̂RI, β̂OLS, and β̂
w
RI.
unsurprising since the true data generating process is a linear model. Finally, covariate adjustment
slightly improves the power of the RI estimator. Overall, in the scenarios we consider, we only
achieve decent levels of power in large samples, although there seems to be reasonable power for
the sample size in the data application, n = 3, 586.
6.2 LATE estimators
We next simulate completely randomized experiments with noncompliance to evaluate the finite
sample performance of the tests for systematic treatment effect variation among Compliers based
on β̂c,RI and β̂TSLS. We first generated a complete dataset as in the ITT case above, and then
assigned strata membership to all units with probabilities proportional to their covariates. For
Always Takers we then set Yi(0) = Yi(1), and for Never Takers, Yi(1) = Yi(0). The overall ITT is
now reduced to 0.21 (due to the 0 effects of Never Takers and Always Takers), although the CACE
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is still approximately 0.3. The proportion of Compliers is approximately 68%.
The Compliers have the systematic and idiosyncratic effects described as above. We tested for
the presence of systematic variation for Compliers under the exclusion restrictions. Figure 2 shows
the power of these tests for our RI and TSLS estimators. First, in this scenario, the 2SLS and
the RI estimators are virtually equivalent; the additional adjustment provided by TSLS does not
add significantly to the precision. We see the tests are valid (they even appear conservative) for
cases (a) and (c). Power is reduced compared to the ITT simulation; this is reasonable as power
is effectively a function of the number of Compliers, with additional uncertainty due to partial
information about the identity of Compliers.
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Figure 2: Power of the tests based on β̂c,RI and β̂TSLS.
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7 Application to the Head Start Impact Study
Established in 1965, Head Start is the largest Federal preschool program in the United States,
serving nearly 1 million low-income three- and four-year-old children each year at a cost of over
$7 billion (Administration for Children and Families, 2015). Researchers and policymakers have
debated Head Start’s effectiveness since its inception, with early randomized trials finding limited
impacts (e.g., Westinghouse Learning Corporation, 1969) and quasi-experimental studies showing
much larger effects (e.g., Currie and Thomas, 1995). Designed in part to settle this debate, the
Head Start Impact Study (HSIS) is a large-scale, nationally representative randomized trial of Head
Start first launched in 2002 (Puma et al., 2010). The Congressional mandate for HSIS included
two broad questions: (1) the program’s overall impact, and (2) how impacts vary across children
and centers. The policy debate has largely focused on this first question; HSIS only found modest
average effects on a range of children’s cognitive and social-emotional outcomes. However, both the
original study and several recent papers argue that these topline results mask important treatment
effect variation (e.g., Bloom and Weiland, 2014; Bitler et al., 2014; Ding et al., 2016; Walters,
2015; Feller et al., 2016). Understanding such variation is critical both for assessing the program’s
benefits and costs and for improving the practice and science of early childhood education.
HSIS collected a rich set of covariates about children and their families, including pre-test score,
child’s age, child’s race, child’s home language, mother’s education level, and mother’s marital
status. At the same time, many potentially important covariates are unavailable. For instance,
while families must be low-income to be eligible for Head Start, HSIS does not include information
on families’ actual income nor other financial details that could be important predictors of program
impact. In addition, Feller et al. (2016) and others argue that that the setting in which a child
would otherwise receive care is an important source of impact variation, although this is not directly
observable.
We now use the methods outlined above to assess treatment effect variation in HSIS. The
original study included n = 4, 400 total children, with n1 = 2, 644 in the treatment group and
n0 = 1, 796 in the control group. Following earlier analyses (Ding et al., 2016) and to simplify
exposition, we restrict our attention to a complete-case subset of the HSIS, with n1 = 2, 238 in the
treatment group and n0 = 1, 348 in the control group (so p1 ≈ 0.62 and p0 ≈ 0.38). Our outcome
of interest is the Peabody Picture Vocabulary Test (PPVT), a widely used measure of cognitive
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ability in early childhood. To assess treatment effect variation, we consider the full set of child-
and family-level covariates used in the original HSIS analysis of Puma et al. (2010), including those
mentioned above. After creating dummy variables for factors (e.g., re-coding race), the covariate
matrix has 17 columns. See Figure 3b for a complete list.
7.1 Decomposing variation in the ITT effect
We first explore treatment effect variation for the ITT estimate, beginning with estimating system-
atic treatment effect variation. We examine three estimators: the randomization-based and OLS
estimators discussed in Section 3, β̂RI and β̂OLS, and the corresponding model-assisted version of
the RI estimator discussed in the Supplementary Material, β̂wRI. For this latter estimator, we use all
available covariates to adjust the standard estimators, that is, W is the entire vector of covariates.
Omnibus test for systematic treatment effect variation. We begin by using these estima-
tors for an omnibus test of whether any treatment effect variation is explained by the full set of
covariates. The p-values for the unadjusted β̂RI estimator and model-assisted β̂
w
RI are 0.39 and 0.25,
respectively, which do not show any evidence of treatment effect variation. The OLS estimator,
however, shows much stronger evidence with p = 0.005.
Importantly, all three estimators are based on the same underlying assumptions: the random-
ization itself justifies all three p-values. And while we expect the unadjusted β̂RI to have the lowest
power, it is instructive that the p-value for β̂OLS is substantially smaller than the p-value for the
covariate-adjusted β̂wRI. As we discuss in Section 3.2, β̂OLS can account for covariate imbalance
across experimental arms by estimating the Sxx matrix separately for the treatment and control
groups. By contrast, β̂RI does not address imbalance in X and instead attempts to residualize out
the Y in order to get a more precise estimate of the relationship of the X to Y for each treatment
arm. Based on the discrepancy in p-values, adjusting for baseline imbalance is clearly important in
this example.
Treatment effect R2τ . Next, we examine how much of the variation could be explained by our
covariates. Figure 3a shows values of the treatment effect R2τ using β̂
w
RI to estimate the systematic
variation. Results are nearly identical using the other estimators. In the worst case of perfect
negative dependence between potential outcomes (not shown), the treatment effect R2τ could be as
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Figure 3: Treatment effect R2τ , with sensitivity parameter, ρ ∈ [0, 1].
low as 0.01. Assuming that this dependence is nonnegative, the treatment effect R2τ ranges from
0.03 to 0.76. While the estimate is clearly sensitive to the unidentifiable sensitivity parameter, the
covariates explain a substantial proportion of treatment effect variation for values of ρ near 1.
We can also use this framework to assess the relative importance of each covariate in terms of
explaining overall treatment effect variation. To do this, we use the model-assisted RI estimator,
β̂wRI, adjusting for all covariates (i.e., dim(W ) = 17) but restricting systematic treatment effect
variation to one covariate at a time. Note that we consider factors (e.g., race) as a group. Figure 3b
shows the resulting estimates for the upper bound of R2τ , with lower bound estimates all below 0.01.
Having a mother who is a recent immigrant and dual language learner status (which are highly
correlated in practice) could each explain a substantial proportion of treatment effect variation,
consistent with previous results from Bloom and Weiland (2014) and Bitler et al. (2014). This is
not true for other covariates, like mother’s education level.
Negative correlation between treatment effect and control potential outcomes. Fi-
nally, we test whether the individual-level idiosyncratic treatment effects, {εi}ni=1, are negatively
correlated with the control potential outcomes, {Yi(0)}ni=1, extending results from Raudenbush and
Bloom (2015). As outlined in the Supplementary Material, we do so by testing whether the variance
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of {Y obsi −XTi β̂wRI : Ti = 1} is smaller than the variance of {Y obsi : Ti = 0}. This yields a p-value
of 0.02, which suggests that the unexplained treatment effect is indeed larger for smaller values of
the control potential outcomes. This result is consistent with findings from Bitler et al. (2014) who
use a quantile treatment effect approach.
7.2 Incorporating noncompliance
As with many social experiments, there is substantial noncompliance with random assignment in
HSIS. In the analysis sample we consider here, the estimated proportion of compliance types is
pic = 0.69 for Compliers, pia = 0.13 for Always Takers, and pin = 0.18 for Never Takers. Given the
exclusion restrictions for Always Takers and Never Takers, the treatment effect is therefore zero (by
assumption) for over 30 percent of the sample, suggesting that noncompliance will be an important
component of treatment effect variation.
In the setting with noncompliance, we focus on two estimators for systematic treatment effect
variation among Compliers: the randomization-based estimator, β̂c,RI, and the Two-Stage Least
Squares estimator, β̂TSLS. We first use these estimators to construct omnibus tests for systematic
treatment effect variation among Compliers. Tests using both estimators show strong evidence for
such variation, with p-value 0.02 using β̂c,RI and p-value 0.01 using β̂TSLS.
Finally, we turn to decomposing the overall treatment effect. As in the ITT case, we assume that
the potential outcomes have a nonnegative correlation. Figure 3a shows the treatment effect R2
among Compliers, which ranges from R2τ,c = 0.05 to R
2
τ,c = 0.68. Next, we can calculate treatment
effect variation due to noncompliance, R2τ,U . In the case of HSIS, this is relatively small—between
0.01 and 0.16—in part because the overall treatment effect is fairly small. Therefore, the overall
treatment effect decomposition due to both covariates and noncompliance, R2τ,UX , is quite close
to R2τ,c, as shown in Figure 3a. Taken together, these estimates suggest that there is indeed
important treatment effect variation that is neither captured by pre-treatment covariates nor by
noncompliance, consistent with previous results in Ding et al. (2016).
8 Conclusion
In this paper, we propose a broad, flexible framework for assessing and decomposing treatment
effect variation in randomized experiments with and without noncompliance. In general, we believe
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this is a natural setup for researchers to formulate and investigate a broad range of questions about
impact heterogeneity (e.g., Heckman et al., 1997). Applications include assessing underlying causal
mechanisms and targeting treatments based on individual-level characteristics. Understanding such
variation is also important for the design of experiments. Djebbari and Smith (2008), for example,
argue that characterizing the size of the idiosyncratic treatment effect is useful for determining the
value of additional data collection.
We briefly note several directions for future work. First, our primary purpose was to propose a
framework for analysis rooted in and justified by the randomization itself. As a result, we focused
on the core properties of several relatively simple versions of linear regression and TSLS. We did
not, however, fully explore their practical and finite-sample properties. For example, in future
work, we hope to determine the settings in which model assistance will most improve estimation
and assess the increased power of the OLS approach versus the unbiased RI approach. We are
also investigating how to connect model assisted and OLS approaches to take advantage of both
methods of precision gain. Similarly, there is still much potential improvement in determining ways
of characterizing the degree of heterogeneity, such as with an effect size for the systematic variation.
Second, a natural extension is to use more complex methods to estimate systematic treatment
effects, such as via hierarchical models (Feller and Gelman, 2015) or via machine learning meth-
ods (Wager and Athey, 2017), extending the results for the omnibus test and treatment effect
R2τ accordingly. While the guarantees from randomization are clearly weaker in such settings,
researchers can assess these tradeoffs themselves. For example, hierarchical modeling would be
especially useful in the Head Start Impact Study due to the multi-site design (Bloom and Weiland,
2014).
Third, a question of increasing practical importance is the generalizability of experimental
results to a given target population (Stuart et al., 2011). We believe that the treatment effect
R2τ is a critical measure for assessing the credibility of these generalizations. In short, if there is
substantial idiosyncratic treatment effect variation, i.e., R2τ is small, then researchers should be
wary of using observed covariates to extrapolate treatment effects.
Finally, a question is how to extend this treatment effect variation framework to non-randomized
settings. While the results would necessarily rest on much stronger assumptions, many settings
already use an as-if-randomized framework, such as in observational studies (Rosenbaum, 2002;
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Imbens and Rubin, 2015). Under this approach, extensions should be natural.
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Supplementary Material
for
“Decomposing Treatment Effect Variation”
Appendix A gives all the proofs and Appendix B provides the additional commentary mentioned
in the main text. The finite population central limit theorem (FPCLT) we use for our asymptotic
proofs is Theorem 5 of Li and Ding (2017), which requires some mild moment conditions on the
covariates and potential outcomes, as outlined in the main text.
Appendix A Lemmas and Proofs
Before we prove Theorem 1, we provide a few lemmas to ease the notational burden and amount of
algebra of subsequent calculations. These lemmas allow us to derive expressions for our estimators
in terms of matrix algebra rather than the summation-style approach typically seen for Neyman-
style derivations in the literature.
To begin, let 1n = (1, . . . , 1)
T and 0n = (0, . . . , 0)
T be column vectors of length n, and In be the
n × n identity matrix. Then Sn = In − n−11n1Tn is the projection matrix orthogonal to 1n with
Sn1n = 0n. Under this formulation, the covariance matrix of the treatment assignment vector is a
scaled projection matrix orthogonal to 1n, as shown in the following lemma.
Lemma A.1. The treatment assignment vector T of a completely randomized experiment has
E(T ) =
n1
n
1n, cov(T ) =
n1n0
n(n− 1)Sn.
Proof of Lemma A.1. The conclusions follow from
E(Ti) =
n1
n
, var(Ti) =
n1n0
n2
, cov(Ti, Tj) = − n1n0
n2(n− 1) , (i 6= j).
The projection matrix Sn acts as a covariance operator as illustrated by the following lemma.
Lemma A.2. Let Ui,Vi ∈ RK be column vectors of length K. Define U = [U1,U2, . . . ,Un] and
V = [V1,V2, . . . ,Vn] ∈ RK×n as two matrices of dimension K × n. If U¯ = n−1
∑n
i=1Ui = n
−1U1
and V¯ = n−1
∑n
i=1 Vi = n
−1V1, then
USnVT =
n∑
i=1
(Ui − U¯)(Vi − V¯ )T. (A.1)
1
In particular, when Ui = Vi,
VSnVT =
n∑
i=1
(Vi − V¯ )(Vi − V¯ )T = (n− 1)S(V ).
Proof of Lemma A.2. The left hand side of (A.1) is equal to
USnVT = UVT − n−1 (U1n) (V1n)T =
n∑
i=1
UiV
T
i − n−1(nU¯)(nV¯ )T =
n∑
i=1
UiV
T
i − nU¯ V¯ T,
which is the same as the right hand side of (A.1).
Theorem 1: A generalized, vector-outcome version of Neyman. To prove the generalized
Neyman result, we bundle our vector potential outcomes into matrices and use the above lemmas
to obtain their covariance matrix. The theorem is exact, no asymptotics. Using the FPCLT to
show that the estimator has an approximately Normal distribution, allowing for classic testing and
inference, is a separate, subsequent step.
Proof of Theorem 1. Define V1 = [V1(1), . . . ,Vn(1)] and V0 = [V1(0), . . . ,Vn(0)] as the matrices of
the potential outcomes. Then the Neymanian simple difference in means estimator has the following
representation:
τ̂V = V¯
obs
1 − V¯ obs0
=
1
n1
n∑
i=1
TiVi(1)− 1
n0
n∑
i=1
(1− Ti)Vi(0)
=
1
n1
V1T − 1
n0
V0 (1− T )
=
(V1
n1
+
V0
n0
)
T − 1
n0
V01.
Now the unbiasedness of τ̂V follows from the linearity of the expectation and Lemma A.1. For
the covariance, note the second term in the above is constant, and so is not involved. Applying
Lemmas A.1 and A.2, we can obtain the covariance matrix of τ̂V :
cov(τ̂V ) =
(V1
n1
+
V0
n0
)
cov(T )
(V1
n1
+
V0
n0
)T
=
n1n0
n(n− 1)
(V1
n1
+
V0
n0
)
Sn
(V1
n1
+
V0
n0
)T
=
n1n0
n(n− 1)
(
1
n21
V1SnVT1 +
1
n20
V0SnVT0 +
1
n1n0
V0SnVT1 +
1
n1n0
V1SnVT0
)
=
n0
nn1
S{V (1)}+ n1
nn0
S{V (0)}+ 1
n(n− 1)(V0SnV
T
1 + V1SnVT0).
2
To simplify the third term, we use the fact abT + baT = aaT + bbT− (a− b)(a− b)T for two column
vectors a and b, we have
{Vi(1)− V¯ (1)}{Vi(0)− V¯ (0)}T + {Vi(0)− V¯ (0)}{Vi(1)− V¯ (1)}T
= {Vi(1)− V¯ (1)}{Vi(1)− V¯ (1)}T + {Vi(1)− V¯ (1)}{Vi(1)− V¯ (1)}T
−{Vi(1)− Vi(0)− V¯ (1) + V¯ (0)}{Vi(1)− Vi(0)− V¯ (1) + V¯ (0)}T.
Summing over i = 1, . . . , n and applying Lemma A.2, we have
V0SnVT1
n− 1 +
V1SnVT0
n− 1 = S{V (1)}+ S{V (0)} − S{V (1)− V (0)}.
Therefore, the covariance of τ̂V can be simplified as:
cov(τ̂V ) =
n0
nn1
S{V (1)}+ n1
nn0
S{V (0)}+ 1
n
[S{V (1)}+ S{V (0)} − S{V (1)− V (0)}]
=
S{V (1)}
n1
+
S{V (0)}
n0
− S{V (1)− V (0)}
n
.
Theorem 2: Behavior of β̂RI. To show properties of β̂RI we express the systematic variation
as a vector of new potential outcomes of the original outcome scaled by the different covariates of
interest. This allows for immediate use of Theorem 1.
Proof of Theorem 2. Because Ŝxt is the sample mean for {XiY obsi : Ti = t, i = 1, . . . , n} =
{XiYi(t) : Ti = t, i = 1, . . . , n}, it is unbiased for the population mean Sxt. Thus, the estima-
tor β̂RI is also unbiased for β as S
−1
xx is fixed and the expectation is linear. Its sampling covariance
over all possible randomizations is
cov(β̂RI) = S
−1
xx cov(Ŝx1 − Ŝx0)S−1xx .
Therefore, we need only to obtain the covariance of
Ŝx1 − Ŝx0 = 1
n1
n∑
i=1
TiXiY
obs
i −
1
n0
n∑
i=1
(1− Ti)XiY obsi ,
which is the difference between the sample means of {XiYi(1) : i = 1, . . . , n} and {XiYi(0) : i = 1, . . . , N}
under treatment and control. Viewing XiY
obs
i as a vector outcome in a completely randomized
experiment, we can apply Theorem 1 to obtain
cov(Ŝx1 − Ŝx0) = S{XY (1)}
n1
+
S{XY (0)}
n0
− S(Xτ)
n
,
3
which completes the proof.
Theorem 3: Behavior of β̂OLS. We first use the well-known fact that the estimate from a
OLS model with treatment fully interacted with covariates is equivalent to separate regressions of
outcome onto covariates for the control and treatment groups. This means we can obtain γ̂OLS
by running a regression of Y obs onto X using the control group data, and γ̂ + βOLS by running
regression of Y obs onto X using the treatment group data, giving estimated coefficients of
γ̂OLS = Ŝ
−1
xx,0Ŝx0
and
β̂OLS = Ŝ
−1
xx,1Ŝx1 − Ŝ−1xx,0Ŝx0.
As a quick heuristic argument for this, consider that the maximization problem for the interacted
model will separate into two components, one for each group. Then re-parameterize to get the
above.
We now prove the properties of β̂OLS. Here we have to use asymptotics for the entire theorem,
unlike the case of β̂RI, where the mean and covariance are exact and the asymptotics are only
needed for the asymptotic normality of the estimator.
Proof of Theorem 3. First expand the difference of β̂OLS and β as
β̂OLS − β = Ŝ−1xx,1(Ŝx1 − Ŝxx,1γ1)− Ŝ−1xx,0(Ŝx0 − Ŝxx,0γ0),
This will be close to the related quantity of
∆ = S−1xx (Ŝx1 − Ŝxx,1γ1)− S−1xx (Ŝx0 − Ŝxx,0γ0). (A.2)
For the above to make sense and hold, we here need our asymptotic framework. In particular,
we need the associated moment conditions described in the main text. We next observe that the
difference between β̂OLS − β and ∆ is of higher order, because
(β̂OLS − β)−∆ = (Ŝ−1xx,1 − S−1xx )(Ŝx1 − Ŝxx,1γ1)− (Ŝ−1xx,0 − S−1xx )(Ŝx0 − Ŝxx,0γ0) (A.3)
= OP (n
−1/2)OP (n−1/2)−OP (n−1/2)OP (n−1/2) = OP (n−1), (A.4)
following from the FPCLT for the four terms in (A.3). This is an argument commonly used in the
survey sampling literature for ratio estimators (Cochran, 1977).
4
We next focus on the asymptotic distribution of ∆, because the asymptotic distribution of
β̂OLS − β will be the same. Further simplify (A.2) as
∆ = S−1xx
[
1
n1
n∑
i=1
TiXiei(1)− 1
n0
n∑
i=1
(1− Ti)Xiei(0)
]
, (A.5)
where ei(1) = Yi(1)−XTiγ1 and ei(0) = Yi(0)−XTiγ0 are the residual potential outcomes. (To see
the above, note, for example, that both Ŝx1 and Ŝxx,1 are sums over the treatment units, and we
can factor out an Xi to get Xi times the difference in the Yi and predicted Yi.)
Applying Theorem 1 to the vector outcome Xe, we obtain the covariance matrix of ∆, to which
β̂OLS − β converges to due to (A.4). The asymptotic normality follows from the representation
(A.5) and the FPCLT.
Theorem 4: Bounds for R2τ . To prove Theorem 4, we need to invoke the following Fre´chet–
Hoeffding inequality (Hoeffding, 1941; Fre´chet, 1951; Heckman et al., 1997; Aronow et al., 2014).
Lemma A.3. If we know only the marginal distributions of two random variables X ∼ FX(x) and
Y ∼ FY (y), then E(XY ) can be sharply bounded by∫ 1
0
F−1X (u)F
−1
Y (1− u)du ≤ E(XY ) ≤
∫ 1
0
F−1X (u)F
−1
Y (u)du.
Lemma A.3 immediately implies the following bound for var(X − Y ) if E(X − Y ) = 0.
Lemma A.4. If we know only the marginal distributions X ∼ FX(x), Y ∼ FY (y) and E(X−Y ) =
0, then var(X − Y ) can be sharply bounded by∫ 1
0
{F−1X (u)− F−1Y (u)}2du ≤ var(X − Y ) ≤
∫ 1
0
{F−1X (u)− F−1Y (1− u)}2du
Proof of Lemma A.4. The variance var(X − Y ) can be decomposed as
var(X − Y ) = E(X − Y )2 = E(X2) + E(Y 2)− 2E(XY ),
which depends on the following three terms:
E(X2) =
∫
x2dFX(x) =
∫ 1
0
{F−1X (u)]}2du,
E(Y 2) =
∫ 1
0 {F−1Y (u)}2du =
∫ 1
0
{F−1Y (1− u)}2du,∫ 1
0
F−1X (u)F
−1
Y (1− u)du ≤ E(XY ) ≤
∫ 1
0
F−1X (u)F
−1
Y (u)du.
Plug the above expressions into the variance of X − Y to obtain the desired bounds.
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Applying Lemma A.4, we can easily prove Theorem 4.
Proof of Theorem 4. Because Sττ = Sδδ + Sεε, we need only to bound Sεε, which is the finite
population variance of εi = {Yi(1) − XTiγ1} − {Yi(0) − XTiγ0} = ei(1) − ei(0). We can identify
the marginal distributions of {ei(1) : i = 1, . . . , n} and {ei(0) : i = 1, . . . , n}, and also know that
n−1
∑n
i=1 εi = 0. Therefore, the bounds in Lemma A.4 imply the bounds in Theorem 4.
Theorem 5: Sensitivity analysis.
Proof of Theorem 5. The joint distribution of (U1, U0) is
C(u1, u0) = P (U1 ≤ u1, U0 ≤ u0)
= ρP (U0 ≤ u1, U0 ≤ u0) + (1− ρ)P (V0 ≤ u1, U0 ≤ u0)
= ρmin(u1, u0) + (1− ρ)u1u0.
Therefore, the distribution function C(u1, u0) is a weighted average of min(u1, u0) = CR(u1, u0)
and u1u0 = CI(u1, u0), i.e., the joint distributions when U1 = U0 and U1 U0, respectively.
According to Nelsen (2007, Theorem 5.1.6), Spearman’s rank correlation coefficient between
e(1) and e(0) is
12
∫ 1
0
∫ 1
0
{C(u1, u0)− u1u0}du1du0 = 12ρ
∫ 1
0
∫ 1
0
{min(u1, u0)− u1u0}du1du0
= 12ρ
(
2
∫ 1
0
du1
∫ u1
0
u0du0 − 1
4
)
= 12ρ(1/3− 1/4) = ρ.
To complete the proof of the theorem, we need only to show that the covariance between e(1)
and e(0) is linear in ρ, which follows from∫ 1
0
∫ 1
0
F−11 (u1)F
−1
0 (u0)dC(u1, u0)
= ρ
∫ 1
0
∫ 1
0
F−11 (u1)F
−1
0 (u0)dCR(u1, u0) + ρ
∫ 1
0
∫ 1
0
F−11 (u1)F
−1
0 (u0)dCI(u1, u0)
= ρ
∫ 1
0
F−11 (u)F
−1
0 (u)du+ (1− ρ)
∫ 1
0
F−11 (u)du
∫ 1
0
F−10 (u)du.
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Theorem 6: Extending to non-compliance. Theorem 6 shows how to estimate the outcome-
to-covariate relationships of the Compliers by estimating different aggregate covariance relationships
across all the strata for different observed groups and then taking differences. Due to the exclusion
restriction for the Never Takers and Always Takers, this gives our desired relationships for the
Compliers only.
First, a small bit of notation of, due to the exclusion restrictions for Never Takers and Always
Takers, defining the population covariance between X and Y (1) = Y (0) within stratum U = a and
U = n as
Sx.,u =
1
nu
n∑
i=1
I(Ui=u)XiYi(1) =
1
nu
n∑
i=1
I(Ui=u)XiYI(0), (u = a, n).
Proof of Theorem 6. We first create an estimator for Sxx,c. From the observed data with (Ti, Di) =
(1, 1), we have
E
{
1
n1
n∑
i=1
TiDiXiX
T
i
}
= E
{
1
n1
n∑
i=1
TiI(Ui=a)XiX
T
i +
1
n1
n∑
i=1
TiI(Ui=c)XiX
T
i
}
= piaSxx,a + picSxx,c. (A.6)
Similar to (A.6), we have
E
{
1
n1
n∑
i=1
Ti(1−Di)XiXTi
}
= pinSxx,n, (A.7)
E
{
1
n0
n∑
i=1
(1− Ti)DiXiXTi
}
= piaSxx,a, (A.8)
E
{
1
n0
n∑
i=1
(1− Ti)(1−Di)XiXTi
}
= pinSxx,n + picSxx,c. (A.9)
Subtracting the left sides of (A.8) from (A.6), or subtracting the left sides of (A.7) from (A.9), give
unbiased estimators for picSxx,c.
Second, analogous to the Sxx,c, we consider the sample covariances between X and Y
obs to
obtain estimators for Sx1,c and Sx0,c. From the observed data with (Ti, Di) = (1, 1), we have
E
{
1
n1
n∑
i=1
TiDiXiY
obs
i
}
= E
{
1
n1
n∑
i=1
TiI(Ui=a)XiYi(1) +
1
n1
n∑
i=1
TiI(Ui=c)XiYi(1)
}
= piaSx.,a + picSx1,c. (A.10)
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Similar to (A.10), we have
E
{
1
n1
n∑
i=1
Ti(1−Di)XiY obsi
}
= pinSx.,n, (A.11)
E
{
1
n0
n∑
i=1
(1− Ti)DiXiY obsi
}
= piaSx.,a, (A.12)
E
{
1
n0
n∑
i=1
(1− Ti)(1−Di)XiY obsi
}
= pinSx.,n + picSx0,c. (A.13)
Subtracting (A.12) from (A.10), and subtracting (A.11) from (A.13), we obtain the results in
(15).
Corollary 3: Behavior of β̂c,RI. Theorem 6 shows how to obtain unbiased estimates of the
components of our estimator, which we can then plug in to obtain a consistent estimator of βc. We
next show how this plug-in estimator behaves.
Proof of Corollary 3. First we write
β̂c,RI − βc = (Ŝxx,11 − Ŝxx,01)−1{Ŝx1,11 − Ŝx0,01 − (Ŝxx,11 − Ŝxx,01)γ1c}
−(Ŝxx,00 − Ŝxx,10)−1{Ŝx0,00 − Ŝx1,10 − (Ŝxx,00 − Ŝxx,10)γ0c},
second we introduce
∆c = (picSxx,c)
−1{Ŝx1,11 − Ŝx0,01 − (Ŝxx,11 − Ŝxx,01)γ1c}
−(picSxx,c)−1{Ŝx0,00 − Ŝx1,10 − (Ŝxx,00 − Ŝxx,10)γ0c},
third we observed that the difference between β̂c,RI − βc and ∆c has higher order following the
same argument as (A.4). Therefore, we need only to find the asymptotic distribution of ∆c.
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Simple algebra gives
∆c = (picSxx,c)
−1
[ 1
n1
n∑
i=1
TiDiXiYi(1)− 1
n0
n∑
i=1
(1− Ti)DiXiYi(0)
− 1
n1
n∑
i=1
TiDiXiX
T
iγc1 +
1
n0
n∑
i=1
(1− Ti)DiXiXTiγc1
− 1
n0
n∑
i=1
(1− Ti)(1−Di)XiYi(0) + 1
n1
n∑
i=1
Ti(1−Di)XiYi(1)
+
1
n0
n∑
i=1
(1− Ti)(1−Di)XiXTiγc0 −
1
n1
n∑
i=1
Ti(1−Di)XiXTiγc0
]
= (picSxx,c)
−1
[ 1
n1
n∑
i=1
TiI(Ui=a)XiYi(1) +
1
n1
n∑
i=1
TiI(Ui=c)XiYi(1)−
1
n0
n∑
i=1
(1− Ti)I(Ui=a)XiYi(0)
− 1
n1
n∑
i=1
TiI(Ui=a)XiX
T
iγc1 −
1
n1
n∑
i=1
TiI(Ui=c)XiX
T
iγc1 +
1
n0
n∑
i=1
(1− Ti)I(Ui=a)XiXTiγc1
− 1
n0
n∑
i=1
(1− Ti)I(Ui=n)XiYi(0)−
1
n0
n∑
i=1
(1− Ti)I(Ui=c)XiYi(0) +
1
n1
n∑
i=1
TiI(Ui=n)XiYi(1)
+
1
n0
n∑
i=1
(1− Ti)I(Ui=n)XiXTiγc0 +
1
n0
n∑
i=1
(1− Ti)I(Ui=c)XiXTiγc0 −
1
n1
n∑
i=1
TiI(Ui=n)XiX
T
iγc0
]
= (picSxx,c)
−1
{ 1
n1
n∑
i=1
TiXi
[
I(Ui=a)(Yi(1)−XTiγc1) + I(Ui=n)(Yi(1)−XTiγc0) + I(Ui=c)(Yi(1)−XTiγc1)
]
− 1
n0
n∑
i=1
(1− Ti)Xi
[
I(Ui=a)(Yi(0)−XTiγc1) + I(Ui=n)(Yi(0)−XTiγc0) + I(Ui=c)(Yi(0)−XTiγc0)
] }
.
According to the definitions of the residual potential outcomes e′i(1) and e
′
i(0) in the main text, the
above formula reduces to
β˜c,RI − βc = (picSxx,c)−1
[
1
n1
n∑
i=1
TiXie
′
i(1)−
1
n0
n∑
i=1
(1− Ti)Xie′i(0)
]
. (A.14)
The representation in (A.14) implies the asymptotic covariance matrix according to Theorem 1 and
the asymptotic normality of β˜c,RI according to the FPCLT.
Theorem 7: Behavior of β̂TSLS. While the amount of notation and matrix algebra is consider-
ably more in scope, the overall structure of the proof follows the earlier one for the OLS estimator
for the ITT. In particular, we show the estimator asymptotically converges to a more tractable
version that has a fixed portion, and then use the usual covariance argument on the remaining
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terms. Before doing this, we first show the probability limits of the estimator by working through
the matrix algebra.
Proof of Theorem 7. First, we find the probability limits of the TSLS estimators:(
γ̂TSLS
β̂TSLS
)
=
{
1
n
n∑
i=1
(
Xi
TiXi
)
(XTi , DiX
T
i )
}−1{
1
n
n∑
i=1
(
Xi
TiXi
)
Y obsi
}
=
(
n−1
∑n
i=1XiX
T
i n
−1∑n
i=1DiXiX
T
i
n−1
∑n
i=1 TiXiX
T
i n
−1∑n
i=1 TiDiXiX
T
i
)−1(
n−1
∑n
i=1XiY
obs
i
n−1
∑n
i=1 TiXiY
obs
i
)
P−→
(
A B
C D
)−1(
G
H
)
. (A.15)
The above term A is A = Sxx, and terms (B,C,D,G,H) are the population limits of the sample
quantities. We will find each of them. Term B is
B = E
{
1
n
n∑
i=1
DiXiX
T
i
}
= E
{
1
n
n∑
i=1
TiDiXiX
T
i +
1
n
n∑
i=1
(1− Ti)DiXiXTi
}
= E
{
1
n
n∑
i=1
TiI(Ui=a)XiX
T
i +
1
n
n∑
i=1
TiI(Ui=c)XiX
T
i +
1
n
n∑
i=1
(1− Ti)I(Ui=a)XiXTi
}
= p1piaSxx,a + p1picSxx,c + p0piaSxx,a
= piaSxx,a + p1picSxx,c.
Term C is C = E
{
n−1
∑n
i=1 TiXiX
T
i
}
= p1Sxx. Term D is
D = E
{
1
n
n∑
i=1
TiDiXiX
T
i
}
= E
{
1
n
n∑
i=1
TiI(Ui=a)XiX
T
i +
1
n
n∑
i=1
TiI(Ui=c)XiX
T
i
}
= p1piaSxx,a + p1picSxx,c.
Term G is
G = E
{
1
n
n∑
i=1
XiY
obs
i
}
= E
{
1
n
n∑
i=1
TiXiY
obs
i +
1
n
n∑
i=1
(1− Ti)XiY obsi
}
= p1Sx1 + p0Sx0.
Term H is H = E
{
n−1
∑n
i=1 TiXiY
obs
i
}
= p1Sx1. We apply the following formula for the inverse
of a block matrix: (
A B
C D
)−1
=
(
S−1D −A−1BS−1A
−D−1CS−1D S−1A
)
,
where SD = A −BD−1C and SA = D − CA−1B are the Schur complements of blocks D and
A. Omitting some tedious matrix algebra, we obtain
SD = p0picSxx,c(piaSxx,a + picSxx,c)
−1Sxx, SA = p1p0picSxx,c,
10
and the inverse of the block matrix is(
A B
C D
)−1
=
(
p−10 pi
−1
c S
−1
xx (piaSxx,a + picSxx,c)S
−1
xx,c −p−11 p−10 pi−1c S−1xx (piaSxx,a + p1picSxx,c)S−1xx,c
−p−10 pi−1c S−1xx,c p−11 p−10 pi−1c S−1xx,c
)
.
Therefore, according to (A.15), the probability limit of γ̂TSLS is
p−10 pi
−1
c S
−1
xx (piaSxx,a + picSxx,c)S
−1
xx,c(p1Sx1 + p0Sx0)− p−11 p−10 pi−1c S−1xx (piaSxx,a + p1picSxx,c)S−1xx,c(p1Sx1)
= S−1xx Sx0 − piapi−1c S−1xx Sxx,aS−1xx,c(Sx1 − Sx0)
= γ0 − piaS−1xx Sxx,aβc ≡ γ∞, (A.16)
and the probability limit of β̂TSLS is
−p−10 pi−1c S−1xx,c(p1Sx1 + p0Sx0) + p−11 p−10 pi−1c S−1xx,c(p1Sx1) = pi−1c S−1xx,c(Sx1 − Sx0) = βc, (A.17)
where we use Sx1 − Sx0 = pic(Sx1,c − Sx0,c), which is guaranteed by exclusion restrictions.
We next find the asymptotic distribution of β̂TSLS. Following the derivation in Corollary 3, we
first write(
γ̂TSLS
β̂TSLS
)
−
(
γ∞
βc
)
=
{
1
n
n∑
i=1
(
Xi
TiXi
)
(XTi , DiX
T
i )
}−1{
1
n
n∑
i=1
(
Xi(Y
obs
i −XTiγ∞ −DiXTiβc)
TiXi(Y
obs
i −XTiγ∞ −DiXTiβc)
)}
,
then introduce
∆TSLS =
(
A B
C D
)−1{
1
n
n∑
i=1
(
Xi(Y
obs
i −XTiγ∞ −DiXTiβc)
TiXi(Y
obs
i −XTiγ∞ −DiXTiβc)
)}
=
(
A B
C D
)−1(
n−1
∑n
i=1 TiXie
′′
i (1) + n
−1∑n
i=1(1− Ti)Xie′′i (0)
n−1
∑n
i=1 TiXie
′′
i (1)
)
=
(
A B
C D
)−1(
n−1
∑n
i=1 TiXi{e′′i (1)− e′′i (0)}+ n−1
∑n
i=1Xie
′′
i (0)
n−1
∑n
i=1 TiXie
′′
i (1)
)
,
(A.18)
with (A,B,C,D) defined in (A.15) and {e′′i (1), e′′i (0)} defined in Theorem 7, and finally recognize
that the difference between the above two formulas has high order. Again we need only to find
the asymptotic distribution of ∆TSLS. The covariance of the second term on the right hand side of
(A.18) is (dropping the constant sum of Xie
′′(0))
cov
(
n−1
∑n
i=1 TiXi{e′′i (1)− e′′i (0)}
n−1
∑n
i=1 TiXie
′′
i (1)
)
=
1
n2
n1n0
n
( S(Xε) 12 [S{Xe′′(1)} − S{Xe′′(0)}+ S(Xε)]
1
2 [S{Xe′′(1)} − S{Xe′′(0)}+ S(Xε)] S{Xe′′(1)}
)
,
11
where the off-diagonal term comes from the finite population covariance between X{e′′(1)− e′′(0)}
and Xe′′(1). Therefore, according to (A.18), the asymptotic covariance of ∆TSLS is the (2, 2) block
of the following matrix
1
n2
n1n0
n
(
A B
C D
)−1
·( S(Xε) 12 [S{Xe′′(1)} − S{Xe′′(0)}+ S(Xε)]
1
2 [S{Xe′′(1)} − S{Xe′′(0)}+ S(Xε)] S{Xe′′(1)}
)
·
(
A B
C D
)−T
,
which is
1
n2
n1n0
n
{
(p−10 pi
−1
c S
−1
xx,c)S(Xε)(p−10 pi−1c S−1xx,c)T + (p−11 p−10 pi−1c S−1xx,c)S{Xe′′(1)}(p−11 p−10 pi−1c S−1xx,c)T
−(p−10 pi−1c S−1xx,c)[S{Xe′′(1)} − S{Xe′′(0)}+ S(Xε)](p−11 p−10 pi−1c S−1xx,c)T
}
= (picSxx,c)
−1
[S{Xe′′(1)}
n1
+
S{Xe′′(0)}
n0
− S(Xε)
n
]
(picSxx,c)
−1.
The asymptotic normality follows from the representation in (A.18) and the FPCLT.
Theorem 8: Decomposition of variation in non-compliance. The following proof uses two
facts: τa = τn = 0, and τ = picτc.
Proof of Theorem 8. Write the total treatment effect variation as
Sττ =
1
n
n∑
i=1
(τi − τ)2 = 1
n
n∑
i=1
τ2i − τ2
=
1
n
n∑
i=1
I(Ui=c)τ
2
i − pi2c τ2c = pic
(
1
nc
n∑
i=1
I(Ui=c)τ
2
i − τ2c
)
+ pic(1− pic)τ2c ,
the treatment effect variation explained by compliance status as
Sττ,U =
∑
u=c,a,n
piu(τu − τ)2 = pic(τc − picτc)2 + pia(0− picτc)2 + pin(0− picτc)2
= picτ
2
c
{
(1− pic)2 + pic(pia + pin)
}
= pic(1− pic)τ2c ,
and the subtotal treatment effect variation for compliers as
Sττ,c =
1
nc
n∑
i=1
I(Ui=c)(τi − τc)2 =
1
nc
n∑
i=1
I(Ui=c)τ
2
i − τ2c .
Therefore, the above three terms has the relationship Sττ = picSττ,c + Sττ,U .
The decomposition Sττ,c = Sδδ,c + Sεε,c follows immediately from the definition of βc.
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Appendix B More detailed comments
Appendices B.1–B.5 give more details of some technical issues and extensions mentioned in the
main text, and Appendix B.6 contains the proofs of the results in Appendix B.
Appendix B.1 Covariate adjustment to improve efficiency
In the main text, the role of covariates has been to model the treatment effect alone. In general,
we also want to use covariates to reduce sampling variability of β̂RI, just as we can use covariates
to get more precise estimates of the average treatment effect. In particular, the goal is to more
precisely estimate Ŝxt ∈ RK ; because these are the only random components in β̂RI, if we estimate
them more precisely, we estimate β̂RI more precisely as well. Let Wi ∈ RJ denote a vector of
pretreatment covariates without the intercept term. Because Xi and Wi have different roles in
estimation, they may also contain different sets of covariates, though, in practice, X is likely to be
a subset of W .
Following the covariate adjustment approach in survey sampling, we can obtain a model-assisted
estimator for β that uses W to reduce sampling variability. To see this, we need several definitions.
Define W = n−1
∑n
i=1Wi and Sww = n
−1∑n
i=1WiW
T
i , with det(Sww) > 0; define W t and Ŝww,t
as the sample mean and covariance ofW under treatment arm t; define B̂t ∈ RJ×K as the regression
coefficient of Y obsX on W for treatment arm t:
B̂t = Ŝ
−1
ww,t
{
1
nt
n∑
i=1
I(Ti=t)Wi(Y
obs
i Xi)
T
}
.
The model-assisted estimator for Sxt is then
Ŝwxt = Ŝxt − B̂Tt(W¯t − W¯ ), (t = 0, 1).
As a result, we can improve the randomization-based estimator by
β̂wRI = S
−1
xx (Ŝ
w
x1 − Ŝwx0).
Theorem A.1. The model-assisted estimator β̂wRI is consistent for β with asymptotic covariance
S−1xx
[S{E(1)}
n1
+
S{E(0)}
n0
− S(∆)
n
]
S−1xx ,
where Ei(t) = Yi(t)Xi −BTt(Wi − W¯ ) is the residual term and ∆i = Ei(1)−Ei(0).
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The estimator, β̂wRI uses covariates both to estimate treatment effect variation and to reduce
sampling variability. Asymptotically, as long asW is predictive of the marginal potential outcomes,
the model-assisted estimator will improve precision over the unassisted estimators.
Appendix B.2 Fisherian exact inference
When εi = 0 for all i, we can obtain exact inference for β based on the Fisher randomization test
(Rubin, 1980; Rosenbaum, 2002; Ding et al., 2016). With a known β, the null hypothesis
H0(β) : Yi(1)− Yi(0) = XTiβ for all i (A.19)
is sharp in the sense of allowing for full imputation of all missing potential outcomes based on
the observed data. We can perform randomization test using any sensible test statistic measuring
the deviation from the null hypothesis H0(β), for example, the test statistic t(T ,Y
obs;β) can be
the difference-in-means, difference-in-medians or the Kolmogorov–Smirnov statistics comparing two
samples {Y obsi −XTiβ : Ti = 1, i = 1, . . . , n} and {Y obsi : Ti = 0, i = 1, . . . , n}. Then we can obtain
a (1− α) level confidence region for β by inverting a sequence of randomization tests:
CRα = {β : Randomization test fails to reject H0(β) at significance level α}.
The confidence region CRα is exact regardless of the sample size, and it is valid for general designs
of experiments if we use the corresponding assignment mechanism to simulate the null distribution
of the test statistic. Due to the duality between testing and interval estimation, we reject H0(X)
with β1 = 0 in Section 3.3 if CRα∩{β : β1 = 0} is an empty set, which controls the type one error
rate by α.
Appendix B.3 A Variance Ratio Test
Raudenbush and Bloom (2015) have noticed that if the variance of the treatment potential outcome
is smaller than the control potential outcome, then the correlation between the individual treatment
effect and the control potential outcome is negative. This statement does not involve any covariates,
but it can be generalized to incorporate systematic and idiosyncratic treatment effect variation.
Below we give a finite population version of their result.
Theorem A.2. If the finite population variance of {Yi(1) −X ′iβ}ni=1 is smaller than {Yi(0)}ni=1,
then the idiosyncratic treatment effect variation, {εi}ni=1, is negatively correlated with the control
potential outcomes.
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Because the condition in Theorem A.2 depends only on the marginal distributions of the po-
tential outcomes, we propose a formal variance ratio test of it using the observed data, which is a
generalization of a similar theorem in Ding et al. (2016):
Theorem A.3. The variance ratio test with rejection region
log s21 − log s20√
(κ̂1 − 1)/n1 + (κ̂0 − 1)/n0
< Φ−1(α),
has size at least as large as α, where s21 and κ̂1 are the sample variance and kurtosis of {Y obsi −
XTi β̂RI : Ti = 1, i = 1, . . . , n}, and s20 and κ̂0 are the sample variance and kurtosis of {Y obsi : Ti =
0, i = 1, . . . , n}, and Φ−1(α) is the α-th quantile of the standard normal distribution.
For finite population inference, the above test in Theorem A.3 is generally conservative, but for
superpopulation inference, it is asymptotically exact.
Note that Raudenbush and Bloom (2015) and Theorem A.2 are only about detecting a negative
association. Unfortunately, there is no testable condition for a positive association.
Appendix B.4 More on noncompliance: estimating the bounds of the R2s
The component Sττ,U and and the probability pic are directly identifiable according to previous
discussion. Furthermore, Sδδ,c is also identifiable according to the following result.
Corollary A.1. Sδδ,c can be expressed as the expectation of the following quantity:
1
pic
{
1
n
n∑
i=1
(δi − τc)2 − 1
n1
n∑
i=1
Ti(1−Di)(δi − τc)2 − 1
n0
n∑
i=1
(1− Ti)Di(δi − τc)2
}
.
Because pic, δi = X
T
iβc and τc can be estimated by a plug-in approach, Sδδ,c can also be estimated
from the observed data.
In the ITT case, estimation of the residual distributions are straightforward. In the noncompli-
ance case, however, we need more discussion about the estimation of F1c(y) and F0c(y), because Ui
is a latent variable. To avoid notational clatter, we assume that γc1 and γc0 are known; in practice
we can replace them by the randomization-based estimators γ̂c1,RI and γ̂c0,RI, and the consistency
of the final estimator will not be affected. Recall the potential residuals e′i(1) and e
′
i(0) defined in
(17), and its observed value e′i = Tie
′
i(1) + (1− Ti)e′i(0). We define the following quantities
F̂11(y) =
1
n1
∑n
i=1 TiDiI(e′i≤y), F̂10(y) =
1
n1
∑n
i=1 Ti(1−Di)I(e′i≤y),
F̂01(y) =
1
n0
∑n
i=1(1− Ti)DiI(e′i≤y), F̂00(y) = 1n0
∑n
i=1(1− Ti)(1−Di)I(e′i≤y).
(A.20)
Similar to Corollary 3, we have the following results.
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Corollary A.2. For any y,
E{F̂11(y)− F̂01(y)} = picF1c(y), E{F̂00(y)− F̂10(y)} = picF0c(y).
Therefore, we can estimate F1c(y) by {F̂11(y) − F̂01(y)}/pic, and estimate F0c(y) by {F̂00(y) −
F̂10(y)}/pic. As we mentioned before, in practice, we use ê′i instead of e′i in the formulas in (A.20).
Appendix B.5 Proofs of the theorems and corollaries in Appendix B
Proof of Theorem A.1. The population-level OLS regression matrix of Y (t)X onto W is
Bt = S
−1
ww
{
1
n
n∑
i=1
Wi{Yi(t)Xi}T
}
∈ RJ×K .
Define S˜wxt = Ŝxt + B
T
t(W¯ − W¯t) and β˜wRI = S−1xx (S˜wx1 − S˜wx0). According to the same argument
as (A.4), β̂RI and β˜
w
RI have the same asymptotic covariance, and in the following we need only to
discuss the covariance of β˜wRI. Because
S˜wx1 − S˜wx0 =
1
n1
n∑
i=1
Ti
{
Yi(1)Xi +B
T
1(W¯ −Wi)
}− 1
n0
n∑
i=1
(1− Ti)
{
Yi(0)Xi +B
T
0(W¯ −Wi)
}
=
1
n1
n∑
i=1
TiEi(1)− 1
n0
n∑
i=1
(1− Ti)Ei(0)
can be represented as the difference between the sample means of Ei(1) and Ei(0), applying The-
orem 2 we can obtain its covariance:
cov
(
S˜wx1 − S˜wx0
)
=
S{E(1)}
n1
+
S{E(0)}
n0
− S{∆}
n
,
which completes the proof.
Proof of Theorem A.2. For simplicity, we abuse the variance and covariance notation for finite
population. For example, var{Y (0)} = ∑ni=1{Yi(0) − Y¯ (0)}2/(n − 1). If var{Y (1) − XTβ} ≤
var{Y (0)}, then var{Y (0) + ε} ≤ var{Y (0)}. Expanding the left hand side,
var{Y (0)}+ var{ε}+ 2cov{Y (0), ε} ≤ var{Y (0)},
which implies 2cov{Y (0), ε} ≤ −var{ε} < 0.
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Although it is straightforward to prove the conclusion for super population inference of Theorem
A.3 by using Ding et al. (2016, Theorem 2, Supplementary Material) and Slutsky’s Theorem, it
is less obvious to prove the conclusion for finite population inference. To simplify the proof, we
first prove the following lemma. Let (c1, · · · , cn)T and (d1, . . . , dn)T be two vectors of nonnegative
constants with the same mean m > 0 but different variances Scc and Sdd. The difference vector
(c1 − d1, . . . , cn − dn)T has mean zero and variance Sc−d,c−d. Let
θ̂c =
1
n1
n∑
i=1
Tici, θ̂d =
1
n0
n∑
i=1
(1− Ti)di
be two sample means of the treatment and control group, respectively.
Lemma A.5. Under the regularity conditions for the FPCLT, log θ̂c− log θ̂d has asymptotic mean
zero and variance
1
m2
(
Scc
n1
+
Sdd
n0
− Sc−d,c−d
n
)
. (A.21)
Proof of Lemma A.5. According to the FPCLT, we have the following joint asymptotic normality
of θ̂c and θ̂d: (
θ̂c
θ̂d
)
=
(
n−11
∑n
i=1 Tici
n−10
∑n
i=1(1− Ti)di
)
a∼ N
[(
m
m
)
,
(
Vcc Vcd
Vcd Vdd
)]
,
where
Vcc =
n0
n1n
Scc, Vdd =
n1
n0n
Sdd, Vcd = − 1
2n
(Scc + Sdd − Sc−d,c−d).
Applying Taylor expansion atm, we have log θ̂c−log θ̂d = {(θ̂c−m)−(θ̂d−m)}/m+oP (n−1/2), which,
coupled with Neyman (1923)’s variance formula, gives the asymptotic variance of log θ̂c − log θ̂d in
(A.21).
Proof of Theorem A.3. First, as a direct consequence of Lemma A.5, the finite sample variance is
always larger than the super population variance, unless Sc−d,c−d = 0. Therefore, we need only to
show that the test in Theorem A.3 is asymptotically exact for super population inference, and the
asymptotic size of the test is no larger than α for finite population inference.
Second, replacing β by its consistent estimator β̂RI does not affect the asymptotic distribution of
the test statistic, due to Slutsky’s Theorem. For simplicity, we treat β as known in our asymptotic
analysis.
With the two ingredients above, Theorem A.3 follows directly from the variance ratio test in
Ding et al. (2016, Theorem 2, Supplementary Material).
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Proof of Corollary A.1. The conclusion follows from
E
{
1
n1
n∑
i=1
Ti(1−Di)(δi − τc)2
}
= E
{
1
n1
n∑
i=1
TiI(Ui=n)(δi − τc)2
}
=
1
n
n∑
i=1
I(Ui=n)(δi − τc)2,
E
{
1
n0
n∑
i=1
(1− Ti)Di(δi − τc)2
}
= E
{
1
n0
n∑
i=1
(1− Ti)I(Ui=a)(δi − τc)2
}
=
1
n
n∑
i=1
I(Ui=a)(δi − τc)2.
Proof of Corollary A.2. We rewrite
F̂11(y) =
1
n1
n∑
i=1
TiI(Ui=c)I{ei(1)≤y} +
1
n1
n∑
i=1
TiI(Ui=a)I{ei(1)≤y},
F̂10(y) =
1
n1
n∑
i=1
TiI(Ui=n)I{ei(1)≤y},
F̂01(y) =
1
n0
n∑
i=1
(1− Ti)I(Ui=a)I{ei(0)≤y},
F̂00(y) =
1
n0
n∑
i=1
(1− Ti)I(Ui=c)I{ei(0)≤y} +
1
n0
n∑
i=1
(1− Ti)I(Ui=n)I{ei(0)≤y}.
In the above formulas, the random components are the Ti’s, and therefore, the corollary follows
from Lemma A.1 and the linearity of expectations.
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